264 related articles for article (PubMed ID: 18487549)
21. Src kinase inhibitors: an emerging therapeutic treatment option for prostate cancer.
Edwards J
Expert Opin Investig Drugs; 2010 May; 19(5):605-14. PubMed ID: 20367532
[TBL] [Abstract][Full Text] [Related]
22. Constitutive activation of Stat3 by the Src and JAK tyrosine kinases participates in growth regulation of human breast carcinoma cells.
Garcia R; Bowman TL; Niu G; Yu H; Minton S; Muro-Cacho CA; Cox CE; Falcone R; Fairclough R; Parsons S; Laudano A; Gazit A; Levitzki A; Kraker A; Jove R
Oncogene; 2001 May; 20(20):2499-513. PubMed ID: 11420660
[TBL] [Abstract][Full Text] [Related]
23. Novel patented SRC kinase inhibitor.
Lu XL; Liu XY; Cao X; Jiao BH
Curr Med Chem; 2012; 19(12):1821-9. PubMed ID: 22414081
[TBL] [Abstract][Full Text] [Related]
24. Combining Src inhibitors and aromatase inhibitors: a novel strategy for overcoming endocrine resistance and bone loss.
Hiscox S; Barrett-Lee P; Borley AC; Nicholson RI
Eur J Cancer; 2010 Aug; 46(12):2187-95. PubMed ID: 20471823
[TBL] [Abstract][Full Text] [Related]
25. SRC inhibitors and angiogenesis.
Schenone S; Manetti F; Botta M
Curr Pharm Des; 2007; 13(21):2118-28. PubMed ID: 17627544
[TBL] [Abstract][Full Text] [Related]
26. Src signaling in cancer invasion.
Guarino M
J Cell Physiol; 2010 Apr; 223(1):14-26. PubMed ID: 20049846
[TBL] [Abstract][Full Text] [Related]
27. Src inhibitors in lung cancer: current status and future directions.
Rothschild SI; Gautschi O; Haura EB; Johnson FM
Clin Lung Cancer; 2010 Jul; 11(4):238-42. PubMed ID: 20630825
[TBL] [Abstract][Full Text] [Related]
28. Src kinase and pancreatic cancer.
Hilbig A
Recent Results Cancer Res; 2008; 177():179-85. PubMed ID: 18084959
[TBL] [Abstract][Full Text] [Related]
29. Src as a therapeutic target in men with prostate cancer and bone metastases.
Saad F
BJU Int; 2009 Feb; 103(4):434-40. PubMed ID: 19154462
[TBL] [Abstract][Full Text] [Related]
30. Targeting Src family kinases in anti-cancer therapies: turning promise into triumph.
Zhang S; Yu D
Trends Pharmacol Sci; 2012 Mar; 33(3):122-8. PubMed ID: 22153719
[TBL] [Abstract][Full Text] [Related]
31. Src tyrosine kinase as a chemotherapeutic target: is there a clinical case?
Chen T; George JA; Taylor CC
Anticancer Drugs; 2006 Feb; 17(2):123-31. PubMed ID: 16428929
[TBL] [Abstract][Full Text] [Related]
32. Src kinases catalytic activity regulates proliferation, migration and invasiveness of MDA-MB-231 breast cancer cells.
Sánchez-Bailón MP; Calcabrini A; Gómez-Domínguez D; Morte B; Martín-Forero E; Gómez-López G; Molinari A; Wagner KU; Martín-Pérez J
Cell Signal; 2012 Jun; 24(6):1276-86. PubMed ID: 22570868
[TBL] [Abstract][Full Text] [Related]
33. Src signaling pathways in prostate cancer.
Varkaris A; Katsiampoura AD; Araujo JC; Gallick GE; Corn PG
Cancer Metastasis Rev; 2014 Sep; 33(2-3):595-606. PubMed ID: 24522479
[TBL] [Abstract][Full Text] [Related]
34. Structural basis of Src tyrosine kinase inhibition with a new class of potent and selective trisubstituted purine-based compounds.
Dalgarno D; Stehle T; Narula S; Schelling P; van Schravendijk MR; Adams S; Andrade L; Keats J; Ram M; Jin L; Grossman T; MacNeil I; Metcalf C; Shakespeare W; Wang Y; Keenan T; Sundaramoorthi R; Bohacek R; Weigele M; Sawyer T
Chem Biol Drug Des; 2006 Jan; 67(1):46-57. PubMed ID: 16492148
[TBL] [Abstract][Full Text] [Related]
35. SRC inhibitors in metastatic bone disease.
Boyce BF; Xing L; Yao Z; Yamashita T; Shakespeare WC; Wang Y; Metcalf CA; Sundaramoorthi R; Dalgarno DC; Iuliucci JD; Sawyer TK
Clin Cancer Res; 2006 Oct; 12(20 Pt 2):6291s-6295s. PubMed ID: 17062716
[TBL] [Abstract][Full Text] [Related]
36. Synergistic effects of various Her inhibitors in combination with IGF-1R, C-MET and Src targeting agents in breast cancer cell lines.
Stanley A; Ashrafi GH; Seddon AM; Modjtahedi H
Sci Rep; 2017 Jun; 7(1):3964. PubMed ID: 28638122
[TBL] [Abstract][Full Text] [Related]
37. Clinical development of SRC tyrosine kinase inhibitors in lung cancer.
Lee D; Gautschi O
Clin Lung Cancer; 2006 May; 7(6):381-4. PubMed ID: 16800962
[TBL] [Abstract][Full Text] [Related]
38. Src: a potential target for the treatment of triple-negative breast cancer.
Tryfonopoulos D; Walsh S; Collins DM; Flanagan L; Quinn C; Corkery B; McDermott EW; Evoy D; Pierce A; O'Donovan N; Crown J; Duffy MJ
Ann Oncol; 2011 Oct; 22(10):2234-40. PubMed ID: 21357651
[TBL] [Abstract][Full Text] [Related]
39. Tyrosine phosphorylation profiling reveals the signaling network characteristics of Basal breast cancer cells.
Hochgräfe F; Zhang L; O'Toole SA; Browne BC; Pinese M; Porta Cubas A; Lehrbach GM; Croucher DR; Rickwood D; Boulghourjian A; Shearer R; Nair R; Swarbrick A; Faratian D; Mullen P; Harrison DJ; Biankin AV; Sutherland RL; Raftery MJ; Daly RJ
Cancer Res; 2010 Nov; 70(22):9391-401. PubMed ID: 20861192
[TBL] [Abstract][Full Text] [Related]
40. Inhibition of SRC family kinases and receptor tyrosine kinases by dasatinib: possible combinations in solid tumors.
Montero JC; Seoane S; Ocaña A; Pandiella A
Clin Cancer Res; 2011 Sep; 17(17):5546-52. PubMed ID: 21670084
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
